OTCMKTS:CYYNF Cynata Therapeutics (CYYNF) Stock Price, News & Analysis → How to camouflage a factory of 53,000 workers (From Stansberry Research) (Ad) Free CYYNF Stock Alerts $0.11 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.11▼$0.1150-Day Range$0.07▼$0.1152-Week Range$0.11▼$0.11VolumeN/AAverage Volume11 shsMarket Capitalization$15.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Cynata Therapeutics alerts: Email Address Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About Cynata Therapeutics Stock (OTCMKTS:CYYNF)Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.Read More CYYNF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYYNF Stock News HeadlinesMarch 6, 2024 | msn.comCynata Therapeutics treats first patient in aGvHD drug trialMarch 4, 2024 | finance.yahoo.comFirst Patient Treated in Phase 2 GvHD TrialApril 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. August 14, 2023 | markets.businessinsider.comVYNE Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 11, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on C4 Therapeutics (CCCC)August 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CymaBay Therapeutics (CBAY) and Vor Biopharma (VOR)August 10, 2023 | technews.tmcnet.comTScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 19, 2023 | benzinga.comCyteir Therapeutics 10% Owner Sold $106K In Company StockApril 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. May 2, 2023 | finance.yahoo.comDimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior AdvisorNovember 16, 2022 | finance.yahoo.comWe Think Shareholders Are Less Likely To Approve A Pay Rise For Cynata Therapeutics Limited's (ASX:CYP) CEO For NowNovember 4, 2022 | finance.yahoo.comLUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney TransplantationSeptember 26, 2022 | benzinga.comCynata Therapeutics Stock (OTC:CYYNF), Earnings Estimates, EPS, and RevenueMay 26, 2022 | finance.yahoo.comUS FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHDJanuary 14, 2022 | finance.yahoo.comWe Think Cynata Therapeutics (ASX:CYP) Can Afford To Drive Business GrowthDecember 29, 2021 | msn.comHere’s why the Cynata (ASX:CYP) share price is rising todaySeptember 30, 2021 | finance.yahoo.comCynata Enters into a New Strategic Partnership with FujifilmSee More Headlines Receive CYYNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Sanitary paper products Sub-IndustryN/A Current SymbolOTCMKTS:CYYNF CUSIPN/A CIKN/A Webwww.cynata.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares143,280,000Free FloatN/AMarket Cap$15.76 million OptionableNot Optionable Beta0.57 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Kilian KellyMD, CEO & DirectorDr. Jolanta AireyChief Medical OfficerMr. Peter Gordon Webse B.Bus (Age 61)FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary Comp: $91.54kKey CompetitorsBioSig TechnologiesNASDAQ:BSGMOncotelic TherapeuticsOTCMKTS:OTLCMannatechNASDAQ:MTEXCocrystal PharmaNASDAQ:COCPAytu BioPharmaNASDAQ:AYTUView All Competitors CYYNF Stock Analysis - Frequently Asked Questions How have CYYNF shares performed in 2024? Cynata Therapeutics' stock was trading at $0.0720 on January 1st, 2024. Since then, CYYNF shares have increased by 52.8% and is now trading at $0.11. View the best growth stocks for 2024 here. How do I buy shares of Cynata Therapeutics? Shares of CYYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CYYNF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynata Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
